| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305-5468 [H. L. M., A. J. G.], and Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157 [C. K.]
Although p53 inactivation is implicated as a mechanism to explain diminished apoptotic response, it is clear that tumor cells that possess transcriptionally functional p53 can also be resistant to diverse apoptotic stimuli. We hypothesize that oncogenic activation and DNA damage are sufficient stimuli to increase the p53-dependent transcription of Fas and thereby establish a situation in which cell to cell contact could be a selective pressure to either lose p53 function or inactivate components of the Fas death pathway. Examination of genetically matched tumor cell lines that possessed either wild-type or null p53 loci indicated that cells possessing functional p53 increased their surface levels of Fas and Fas ligand (FasL) in response to DNA damage. In contrast, stress induced by changes in the tumor microenvironment such as decreased oxygen did not up-regulate Fas or FasL. Cells with wild-type p53 underwent Fas-mediated killing in the presence of either FasL-expressing killer cells or activating Fas antibodies, whereas cells in which p53 was deleted or inactivated were protected from such killing. Furthermore, Fas and FasL expression and induction became transcriptionally repressed in transformed cells with wild-type p53 with increasing passage, whereas other p53 downstream targets and functions, such as p21 inducibility and cell cycle arrest, remained intact. Repression of the Fas locus could be reverted by treatment with the histone deacetylase inhibitor trichostatin A. These results support a model of tumor progression in which oncogenic transformation drives tumor cells to lose either p53 or their Fas sensitivity as a means of promoting their survival and evade immune surveillance.
This article has been cited by other articles:
|
|
 |
|
  C. Nadal, J. Maurel, R. Gallego, A. Castells, R. Longaron, M. Marmol, S. Sanz, R. Molina, M. Martin-Richard, and P. Gascon FAS/FAS Ligand Ratio: A Marker of Oxaliplatin-Based Intrinsic and Acquired Resistance in Advanced Colorectal Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4770 - 4774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yada, N. Takamura, K. Inagaki-Ohara, M. K. O'Leary, C. Wasem, T. Brunner, D. R. Green, T. Lin, and M. J. Pinkoski The Role of p53 and Fas in a Model of Acute Murine Graft-versus-Host Disease J. Immunol., February 1, 2005; 174(3): 1291 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Sharov, F. Siebenhaar, T. Y. Sharova, N. V. Botchkareva, B. A. Gilchrest, and V. A. Botchkarev Fas Signaling Is Involved in the Control of Hair Follicle Response to Chemotherapy Cancer Res., September 1, 2004; 64(17): 6266 - 6270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Laoag-Fernandez, H. Matsuo, H. Murakoshi, A. L. Hamada, B. K. Tsang, and T. Maruo 3,5,3'-Triiodothyronine Down-Regulates Fas and Fas Ligand Expression and Suppresses Caspase-3 and Poly (Adenosine 5'-Diphosphate-Ribose) Polymerase Cleavage and Apoptosis in Early Placental Extravillous Trophoblasts in Vitro J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4069 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dong and J. Wang Hypoxia Selection of Death-resistant Cells: A ROLE FOR Bcl-XL J. Biol. Chem., March 5, 2004; 279(10): 9215 - 9221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Sheard, S. Uldrijan, and B. Vojtesek Role of p53 in Regulating Constitutive and X-Radiation-Inducible CD95 Expression and Function in Carcinoma Cells Cancer Res., November 1, 2003; 63(21): 7176 - 7184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rajesh, R. A. Stenzel, and S. P. Howard Perillyl Alcohol as a Radio-/Chemosensitizer in Malignant Glioma J. Biol. Chem., September 19, 2003; 278(38): 35968 - 35978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Gurova, O. W. Rokhlin, A. V. Budanov, L. G. Burdelya, P. M. Chumakov, M. B. Cohen, and A. V. Gudkov Cooperation of Two Mutant p53 Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells Cancer Res., June 1, 2003; 63(11): 2905 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, J.-L. Formento, M. Francoual, P. Formento, N. Renee, E. Chamorey, et al. Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses J. Clin. Oncol., June 15, 2002; 20(12): 2832 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lorenzo, C. Ruiz-Ruiz, A. J. Quesada, G. Hernandez, A. Rodriguez, A. Lopez-Rivas, and J. M. Redondo Doxorubicin Induces Apoptosis and CD95 Gene Expression in Human Primary Endothelial Cells through a p53-dependent Mechanism J. Biol. Chem., March 22, 2002; 277(13): 10883 - 10892. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
